The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes
Abstract Background Psoriatic arthritis (PsA) is a chronic inflammatory arthritis which impacts significantly on the quality of life and work capacity of affected individuals. Recent evidence has shown that early control of inflammation in PsA leads to improved long-term outcomes. It is postulated t...
Main Authors: | Gabriele De Marco, Philip Helliwell, Dennis McGonagle, Paul Emery, Laura C. Coates, Elizabeth M. A. Hensor, Helena Marzo-Ortega |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | BMC Musculoskeletal Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12891-017-1659-1 |
Similar Items
-
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01) -
Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
by: Henriëtte M. Y. de Jong, et al.
Published: (2019-09-01) -
CD4 T-Cell Dysregulation in Psoriatic Arthritis Reveals a Regulatory Role for IL-22
by: Amara Ezeonyeji, et al.
Published: (2017-10-01) -
Initial experience with golimumab in clinical practice for ulcerative colitis
by: Luisa Castro-Laria, et al. -
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
by: Michelle L. M. Mulder, et al.
Published: (2020-02-01)